HOXA11 and central nervous system cancer: In-vivo therapeutic applications: For many oncogenic lncRNAs, including XIST (164, 169, 171), NEAT1 (150, 158), CRNDE (173, 175, 176), TUG1 (182, 183), FOXD2-AS1 (190), HOXA11-AS (199, 201), and TP73-AS1 (204, 208), and tumor suppressor lncRNAs, including GAS5 (214, 215), CASC2 (221), MATN1-AS1 (226), animal studies, which are more advanced stages of investigating roles of lncRNAs (255), validated their effect on glioma.